C-CAMP kicks off programme for antimicrobial resistance innovations

C-CAMP kicks off programme for antimicrobial resistance innovations


The Centre for Cellular and Molecular Platforms (C-CAMP) has started an accelerator programme in India to fast-track innovations tackling antimicrobial resistance (AMR).

The programme, which was announced at the Grand Finale of the C-CAMP AMR Quest held in July 2020, has been kicked off with six innovators in therapeutics and diagnostics.

The 12-week long accelerator programme would provide strategic inputs on scientific, clinical, IP, regulatory, and commercialisation aspects, said C-CAMP in a press release.

The programme also includes networking and peer to peer interaction. The 2020 cohort comprises of the following winners of AMR Quest 2020 – Shridhar Narayanan, Director and Chief Scientific Officer of Foundation for Neglected Disease Research (FNDR); Tanay Bhatt, an academician from DBT Institute for Stem Cell Science and Regenerative Medicine, Dhananjay Dendukuri, CEO and Co-Founder of Achira Labs and Chirag Pandya, CEO and Co-Founder of Ampligene India Biotech and following members who received a special mention from the Grand Jury – Dipti Sareen, faculty at Panjab University and Sarath Nair, academician at SRM University.

“The C-CAMP AMR Accelerator is one of the first-ever acceleration support programme in India towards nurturing and sustaining breakthrough innovations in AMR, an emerging threat for healthcare systems across the world. As the COVID-19 pandemic has shown, a widely spreading multi-drug resistant bacteria and or any other MDR-microbial infection will be devastating for our society. C-CAMP as a global catalyzer for AMR innovation is delighted to sow vital seeds through programmes like AMR accelerator to diagnose, treat and prevent such an infection from snowballing into the next pandemic,” said Taslimarif Saiyed, CEO and Director, C-CAMP.

Source link